AU2003272068A8 - Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators - Google Patents

Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators

Info

Publication number
AU2003272068A8
AU2003272068A8 AU2003272068A AU2003272068A AU2003272068A8 AU 2003272068 A8 AU2003272068 A8 AU 2003272068A8 AU 2003272068 A AU2003272068 A AU 2003272068A AU 2003272068 A AU2003272068 A AU 2003272068A AU 2003272068 A8 AU2003272068 A8 AU 2003272068A8
Authority
AU
Australia
Prior art keywords
benzimidazolon
derivatives
potassium channel
cortical neuron
neuron activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2003272068A
Other versions
AU2003272068A1 (en
Inventor
Asher Peretz
Bernard Attali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of AU2003272068A1 publication Critical patent/AU2003272068A1/en
Publication of AU2003272068A8 publication Critical patent/AU2003272068A8/en
Priority to AU2005201685A priority Critical patent/AU2005201685B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2003272068A 2002-10-21 2003-10-21 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators Abandoned AU2003272068A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005201685A AU2005201685B2 (en) 2002-10-21 2005-04-21 Derivatives of N-Phenylanthranilic Acid and 2-Benzimidazolon as Potassium Channel and/or Cortical Neuron Activity Modulators

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41952502P 2002-10-21 2002-10-21
US60/419,525 2002-10-21
PCT/IL2003/000855 WO2004035037A2 (en) 2002-10-21 2003-10-21 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005201685A Division AU2005201685B2 (en) 2002-10-21 2005-04-21 Derivatives of N-Phenylanthranilic Acid and 2-Benzimidazolon as Potassium Channel and/or Cortical Neuron Activity Modulators

Publications (2)

Publication Number Publication Date
AU2003272068A1 AU2003272068A1 (en) 2004-05-04
AU2003272068A8 true AU2003272068A8 (en) 2004-05-04

Family

ID=32108098

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003272068A Abandoned AU2003272068A1 (en) 2002-10-21 2003-10-21 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators

Country Status (6)

Country Link
EP (1) EP1553932A2 (en)
JP (1) JP2006513154A (en)
KR (1) KR20050074493A (en)
AU (1) AU2003272068A1 (en)
CA (1) CA2503075A1 (en)
WO (1) WO2004035037A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
GB0813403D0 (en) * 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
JP7448472B2 (en) * 2017-10-09 2024-03-12 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド Modulators of potassium ion channels and TRPV1 channels and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5032189A (en) * 1973-07-20 1975-03-28
JPS5095285A (en) * 1973-12-26 1975-07-29
JPH05132431A (en) * 1990-03-28 1993-05-28 Nippon Oil & Fats Co Ltd Polymerized pharmaceutical agent and its preparation
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
ITMI962356A1 (en) * 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I USE OF COMPOUNDS DERIVED FROM MOLECULES WITH NON-STEROID ANTI-INFLAMMATORY ACTIVITY FOR THE PREVENTION AND TREATMENT OF
NZ501277A (en) * 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6291442B1 (en) * 1998-02-03 2001-09-18 The General Hospital Corporation Pharmacological modulators of voltage-gated potassium ion channels
AU760250B2 (en) * 1998-12-04 2003-05-08 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation A(beta)42 lowering agents
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
GB0026838D0 (en) * 2000-11-02 2000-12-20 Glaxo Group Ltd Treatment method
US6593349B2 (en) * 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
WO2009037707A2 (en) * 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof

Also Published As

Publication number Publication date
AU2003272068A1 (en) 2004-05-04
KR20050074493A (en) 2005-07-18
WO2004035037A2 (en) 2004-04-29
WO2004035037A3 (en) 2004-06-03
JP2006513154A (en) 2006-04-20
EP1553932A2 (en) 2005-07-20
CA2503075A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
AU2003235403A1 (en) Method of utilizing physiological activity of rare saccharide and compositions containing rare saccharide
AU2003257937A1 (en) Methods and compositions for treatment of dermal conditions
SI2025670T1 (en) Use of 3-phenylthio-1H-indole-1-acetic acid derivatives as modulators of CRTh2 receptor activity
AU2003249549A1 (en) Generalized metronome for modification of biorhythmic activity
AU2003288902A1 (en) Microcapsules and methods of use
AU2003295801A8 (en) Modulation of hif1alpha and hif2alpha expression
AU2003220586A1 (en) Game piece and system and method of use
AU2003270880A1 (en) Mouthpiece devices and methods to allow uv whitening of teeth
EP1511488A4 (en) Human adam-10 inhibitors
AU2003291700A1 (en) Oral hygiene system and method of treatment
IL165397A0 (en) Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
EP1505961A4 (en) Methods of treating allergic reactions
AU2003265972A1 (en) Composition and method to whiten skin
EP1637136A4 (en) Composition having autonomic nerve modulating activity and method of use thereof
AU2003272068A8 (en) Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
AU2003270536A1 (en) Method of treating skin disorders
IL163959A (en) Derivatives of phenyl-sulfonylamino- benzoic acid and pharmaceutical compositions comprising them
AU2003271049A1 (en) Use of amide or ester of sugar and of fatty acid, for treating and/or preventing dry skin
AU2003225161A1 (en) Enhancement of human epidermal melanogenesis
EP1709206A4 (en) Compositions and methods for modulating sirtuin activity
AU2003273362A1 (en) Scrubber and method of using scrubber
AU2003287546A1 (en) Synthetic lactone formulations and method of use
AU2003246861A1 (en) Use of agents that modulate pde11a activity
AU2003224361A1 (en) Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid
AU2003296499A8 (en) Modulation of ppar-alpha expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase